Background
Indigenous communities are disproportionately affected by group A Streptococcus (GAS) infections. We determined the incidence of invasive infections in two Indigenous communities in the U.S. and compared emm types from carriage, pharyngitis, and invasive infections.
Methods
Study activities included: laboratory-based surveillance for invasive GAS infections in White Mountain Apache Tribal lands (WMAT) (2017–2024) and Navajo Nation (NN) (2023–2024); GAS culture of pediatric oropharyngeal carriage samples (2022–2023); and laboratory-based surveillance for pediatric GAS pharyngitis (2023–2024). Emm types were determined by sequencing. We calculated coverage with a 30-valent vaccine in development.
Results
In WMAT, age-standardized rates of invasive infections were 114–270/100,000 in 2017–2020 and 80–99/100,000 in 2021–2024. Predominant emm types varied: 82 predominated in 2017 (67% of isolates), 91 (59%) and 49 (32%) in 2019–2020, and 43 (40%) and 53 (30%) in 2023. In NN, rates were 40–58/100,000 in 2023–2024; common emm types were 53 (28%), 101 (18%), and 12 (16%). Emm types 1, 12, and 53 predominated in pharyngitis, and 1, 12, and 91 in carriage. The percentage of emm types included in the 30-valent vaccine was higher for carriage (86%/72% in WMAT/NN) and pharyngitis (78%/86%) than invasive infections (50%/43%).
Conclusions
Incidence of invasive GAS in these communities was 5–40 times higher than national U.S. estimates (8.2/100,000 in 2022). Emm types varied over time with limited overlap in strains causing carriage/pharyngitis and invasive infections. Findings support expanding GAS surveillance and engaging Indigenous communities during vaccine development and evaluation.